MedTrace Logo

Tumor-Derived FGF19

NCT06068257 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 210

Last updated 2024-12-06

No results posted yet for this study

Summary

Identify and test thresholds, specificity and sensitivity for a potential cancer associated biomarker protein, FGF19, (and associated markers) for detection in human blood in the blood of breast and colorectal in cancer patients, and see if occurs at higher rates than healthy controls

Conditions

Sponsors & Collaborators

  • University of Central Florida

    lead OTHER

Principal Investigators

  • Deborah Altomare, PhD · University of Central Florida College of Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-06-06
Primary Completion
2025-06-30
Completion
2025-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06068257 on ClinicalTrials.gov